Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urologica e Nefrologica 2019 June;71(3) > Minerva Urologica e Nefrologica 2019 June;71(3):201-4

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   Free accessfree

Minerva Urologica e Nefrologica 2019 June;71(3):201-4

DOI: 10.23736/S0393-2249.19.03329-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Current evidence and future perspectives about the role of iXip® in the diagnosis of prostate cancer

Alessandro ANTONELLI 1 , Simone FRANCAVILLA 1, Andrea GALLOTTA 2, Luigi F. DA POZZO 3, Stefania FERRETTI 4, Sandra SIGALA 5, Claudio SIMEONE 1, Vincenzo MIRONE 6, Walter ARTIBANI 7, Angelo PORRECA 8

1 Department of Urology, ASST Spedali Civili, Brescia, Italy; 2 Xeptagen S.p.A., VEGA Science Park, Venice, Italy; 3 Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy; 4 Department of Urology, Parma University Hospital, Parma, Italy; 5 Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; 6 Department of Urology, Federico II University, Naples, Italy; 7 Clinic of Urology, Department of Oncological and Surgical Sciences, Verona University Hospital, University of Verona, Verona, Italy; 8 Department of Urology, Abano Terme General Hospital, Padua, Italy



iXip® (Immune CompleX Predictive Index, Xeptagen, Venice, Italy) is a diagnostic tool which biological bases ground on PSA-IgM complexes. An algorithm merges the data of PSA-IgM and serum total PSA dosage, prostate volume and patient’s age, providing as output a numerical value that correlates with the risk of finding prostate cancer (PCa) at biopsy. The present paper reviews the available evidence and explores future perspective on iXip. A few studies consistently showed that iXip offers better diagnostic accuracy in the diagnosis of PCa than every single parameter composing the index. In detail, for values of iXip below 20% prostatic biopsies were invariably negative, between 20% and 30% only one out of 10 patients had cancer, generally Gleason Score 6, whereas for iXiP>30% the detection rate raised up to 35% and comprised the majority of Gleason score >6 cancers. The PROXIMA study is an ongoing prospective trial that should assess the predictive ability of iXip towards the presence of a clinically significant PCa defined at radical prostatectomy, accounting for clinical, multiparametric magnetic resonance and bioptic data. Preliminary data showed that for iXip values <20% prostatic biopsy could be safely omitted and that the diagnosis of Gleason Score >6 PCa is unlikely for values below 30%.


KEY WORDS: Immune complex diseases; Prostatic neoplasms; Biopsy; Diagnosis; Biomarkers

top of page